2,293 Shares in Natera, Inc. $NTRA Purchased by Perigon Wealth Management LLC

Perigon Wealth Management LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,293 shares of the medical research company’s stock, valued at approximately $622,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Horizon Investments LLC boosted its holdings in shares of Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 44 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares during the last quarter. First Horizon Corp raised its holdings in shares of Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 51 shares during the last quarter. Siemens Fonds Invest GmbH raised its holdings in shares of Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 54 shares during the last quarter. Finally, Alamea Verwaltungs GmbH lifted its position in Natera by 2.9% during the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 62 shares during the period. Institutional investors own 99.90% of the company’s stock.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider directly owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director owned 1,076,198 shares in the company, valued at $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 181,045 shares of company stock valued at $41,330,968. Insiders own 5.05% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research reports. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Barclays reissued an “overweight” rating and set a $340.00 price target on shares of Natera in a report on Friday, August 7th. Sanford C. Bernstein assumed coverage on Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target on the stock. Royal Bank Of Canada upped their price objective on Natera from $275.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Finally, JPMorgan Chase & Co. increased their target price on Natera from $315.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $319.38.

Natera Stock Up 4.3%

NTRA stock opened at $325.07 on Thursday. The business’s 50-day moving average price is $269.73 and its 200-day moving average price is $228.01. The stock has a market cap of $46.86 billion, a P/E ratio of -239.02 and a beta of 1.51. Natera, Inc. has a twelve month low of $156.71 and a twelve month high of $326.03.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter last year, the business earned ($0.74) EPS. The firm’s revenue was up 37.7% compared to the same quarter last year. On average, equities research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.